Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

IGC Pharma, Inc. Common Stock (NY:IGC)

0.2569 -0.0130 (-4.82%)
Streaming Delayed Price Updated: 1:33 PM EST, Feb 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about IGC Pharma, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
News headline image
IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation
Via ACCESS Newswire
News headline image
IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York
Via ACCESS Newswire
News headline image
IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship Network Site, in Richmond, Virginia
Via ACCESS Newswire
News headline image
IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability
Via ACCESS Newswire
News headline image
IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial
Via ACCESS Newswire
News headline image
IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum
Via ACCESS Newswire
News headline image
IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines
Via ACCESS Newswire
News headline image
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75."
Via ACCESS Newswire
News headline image
IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial
Via ACCESS Newswire
News headline image
IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease
Via ACCESS Newswire
News headline image
IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends
Via ACCESS Newswire
News headline image
IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital
Via ACCESS Newswire
News headline image
USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders
Via ACCESS Newswire
News headline image
IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025
Via ACCESS Newswire
News headline image
IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline
Via ACCESS Newswire
News headline image
IGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant"
Via ACCESS Newswire
News headline image
IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences
Via ACCESS Newswire
News headline image
IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders
Via ACCESS Newswire
News headline image
IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease
Via ACCESS Newswire
News headline image
IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial
Via ACCESS Newswire
News headline image
IGC Pharma Announces Preclinical Data Demonstrating TGR-63’s Dual Action on Alzheimer’s Pathology
Via ACCESS Newswire
News headline image
IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial
Via ACCESS Newswire
News headline image
IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection
Via ACCESS Newswire
News headline image
IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada
Via ACCESS Newswire
News headline image
IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette's Syndrome
Via ACCESS Newswire
News headline image
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock. Raising P/T to $4.50."
Via ACCESS Newswire
News headline image
IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City
Via ACCESS Newswire
News headline image
IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's Trial
Via ACCESS Newswire
News headline image
IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1
Via ACCESS Newswire
News headline image
IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of Disease Progression
Via ACCESS Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.